Accueil   Diary - News   All news iDD biotech enters worldwide exclusive licence concerning antibodies and patents related to CK8

iDD biotech enters worldwide exclusive licence concerning antibodies and patents related to CK8

Lyon, 30 March 2017. iDD biotech has announced earlier today the signature of an exclusive worldwide licence with PULSALYS, the Technology Transfer Office of Lyon University, to scale-up and accelerate the development of iDD005 R&D project targeting CK8.

 

CK8 is expressed at the cell surface in cancer cells (eCK8), in particular in colon cancer but also in head and neck (HN) carcinoma, in glioma as well as in lung cancers.

 

iDD biotech, together with Lyon Cancer Research Center (CRCL), hosted by the Centre Léon Bérard (CLB), has developed humanized MAb targeting eCK8 and has gained spectacular in-vivo POC with tumour shrinkage and massive necrosis.

 

These very encouraging results with preclinical animal models support the continued development towards a phase I study of a first in class in human clinical trial.

 

 

 

Read the press release